Gender Dysphoria
Conditions
Brief summary
Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-affirming hormone therapy and in controls
Interventions
Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
Sponsors
Study design
Eligibility
Inclusion criteria
(retrospective analysis of available data as a part of the regular care of subjects with gender dysphoria. All measurements were made at the time of the routine follow-up visits) * age \>= 16 years (Tanner stage IV) and \<= 50 years at the initiation of gender-affirming hormone therapy; * BMI \< 28 kg/m2 at the initiation of cross-sex hormonal treatment.
Exclusion criteria
* hormonal contraception * previous gender-affirming hormonal treatment * previous gender-affirming surgery * recognized syndrome or chromosomal defect, known metabolic or inflammatory disease, skeletal dysplasia, or chronic corticosteroid treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Retrospective analysis of existing data collected as a part of the regular follow-up | Retrospective analysis of data between 2004 and 2019 | Retrospective analysis of existing data :Anthropometric parameters, including systolic blood pressure (SBP), diastolic blood pressure (DBP), body weight and height at fasting state, were measured in all subjects at the occasion of the routine follow-up visits. Body mass index (BMI) was calculated as body weight in kilograms divided by the height in meter squared (kg/m2). Body composition parameters, including lean mass (LM), total body fat (BF), android and gynoid fat, and bone mineral content, were determined using dual-energy X-Ray absorbtiometry (DXA) (GE-Healthcare Lunar iDXA system), biochemical and routine hormonal analysis |
Countries
France